Quest Diagnostics (DGX) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Quest Diagnostics (DGX) PT Lowered to $103 at Mizuho Securities
October 19, 2017 5:19 PM EDTMizuho Securities lowered its price target on Quest Diagnostics (NYSE: DGX) to $103.00 (from $122.00) while maintaining a Buy rating. Analyst Ann Hynes updated 2018 and 2019 adjusted EPS estimates, both decreasing by $0.10 related to the proposed PAMA rule released in September.
Mizuho Securities did not... More
